Growth hormone therapy and treatment outcomes: current clinical practice of the Gulf Cooperation Council

被引：2

作者：

Al Herbish, Abdullah S. ^{[1
]}

Al Alwan, Ibrahim ^{[2
,3
]}

Al Mutair, Angham ^{[2
,3
]}

Al Twaim, Abdulaziz ^{[3
]}

Al Agha, Abdul-Moein ^{[4
]}

Deeb, Asma ^{[5
]}

Abdul-Rasoul, Majedah ^{[6
]}

El-Awwa, Ahmed ^{[7
,8
]}

Al Mushcab, Suzan ^{[9
]}

Esmat, Khaled ^{[10
]}

机构：

[1] Habib Med Grp, Dept Pediat Endocrinol, POB 91877, Riyadh 11643, Saudi Arabia

[2] Kind Saud bin Abdulaziz Univ, Coll Med, Hlth Sci, Riyadh, Saudi Arabia

[3] King Abdul Aziz Med City, Dept Pediat, Riyadh, Saudi Arabia

[4] King Abdulaziz Univ Hosp, Fac Med, Dept Pediat, Jeddah, Saudi Arabia

[5] Mafraq Hosp, Dept Pediat Endocrinol, Abu Dhabi, U Arab Emirates

[6] Kuwait Univ, Fac Med, Dept Pediat, Safat, Kuwait

[7] Hamad Med Corp, Dept Pediat Endocrinol & Diabet, Doha, Qatar

[8] Univ Alexandria Childrens Hosp, Dept Pediat, Alexandria, Egypt

[9] Dhahran Hlth Ctr, Dhahran, Saudi Arabia

[10] Merck Serono Middle East, Dubai, U Arab Emirates

来源：

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2014年 / 9卷 / 04期

关键词：

adherence; diagnosis; growth hormone deficiency; response; therapy;

D O I：

10.1586/17446651.2014.921115

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over the last 20 years, recombinant human growth hormone (somatropin) has been the cornerstone of managing children with growth hormone deficiency (GHD). Although both international and national guidelines for growth hormone (GH) therapy exist, there is currently no consensus on the optimal use of GH therapy in Gulf Cooperation Council (GCC) countries. The goals of GH therapy are to normalize height during childhood, attain normal adult height and correct metabolic abnormalities related to GHD. However, extended use of GH > 50 mg/kg/day may increase frequency of adverse events. Here, we report the proceedings from a meeting of nine GCC pediatric endocrinology experts, which took place in Beirut in November 2011. The meeting was also attended by three European counterparts and aimed to provide consensus on best practice in the management of children with GHD in the GCC based on current local medical and regulatory environments.

引用

页码：319 / 325

页数：7

共 15 条

[1]

Al-Herbish AS, 2000, SAUDI MED J, V21, P536

[2]

Al-Herbish AS, 1999, SAUDI MED J, V20, P766

[3]

Backeljauw Philippe, 2010, Pediatr Endocrinol Rev, V7 Suppl 1, P154

[4] Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children [J].

Bakker, Bert ;

Frane, James ;

Anhalt, Henry ;

Lippe, Barbara ;

Rosenfeld, Ron G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :352-357

[5] A Comparison of Different Definitions of Growth Response in Short Prepubertal Children Treated with Growth Hormone [J].

Bang, P. ;

Bjerknes, R. ;

Dahlgren, J. ;

Dunkel, L. ;

Gustafsson, J. ;

Juul, A. ;

Kristrom, B. ;

Tapanainen, P. ;

Aberg, V. .

HORMONE RESEARCH IN PAEDIATRICS, 2011, 75 (05) :335-345

[6]

Carel JC, 2010, ENDOCR DEV, V18, P40, DOI 10.1159/000316126

[7]

Cassorla Fernando, 2011, Pediatr Endocrinol Rev, V9, P554

[8] Variable Degree of Growth Hormone (GH) and Insulin-Like Growth Factor (IGF) Sensitivity in Children with Idiopathic Short Stature Compared with GH-Deficient Patients: Evidence from an IGF-Based Dosing Study of Short Children [J].

Cohen, Pinchas ;

Germak, John ;

Rogol, Alan D. ;

Weng, Wayne ;

Kappelgaard, Anne-Marie ;

Rosenfeld, Ron G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) :2089-2098

[9] Compliance with growth hormone treatment - Is it a problem? [J].

Hindmarsh, PC ;

Brook, CGD .

HORMONE RESEARCH, 1999, 51 :104-108

[10]

Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990

← 1 2 →